Risk Factors and Multiomics Study of Chronic Kidney Disease Caused by Metabolic Diseases

NCT ID: NCT05476627

Last Updated: 2022-08-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-07-01

Study Completion Date

2027-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

With the development of China's economy, people's living standard have improved, and the dietary structure have changed. Metabolic diseases, such as hypertension, diabetes, hyperuricemia and obesity have gradually become an important health burden in China. The pathophysiological mechanism of renal injury caused by metabolic diseases has always been a hotspot of research. Currently, it is believed that various mechanisms including the activation of Renin-Angiotensin-Aldosterone System, vascular endothelial dysfunction, oxidative stress and inflammatory process may be involved. Although there are differences in renal pathological manifestations caused by different metabolic diseases, the kidney will eventually present ischemic changes and fibrosis with the progression of the disease. So there must be some common pathogenesis. This study is designed to build a disease cohort of patients with chronic kidney disease caused by metabolic diseases, to identify risk factors leading to disease progression and to explore biomarkers for early diagnosis and treatment of kidney damage.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Kidney Diseases Hypertension Diabetes Mellitus Hyperuricemia Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hypertension Group

Biomarkers

Intervention Type DIAGNOSTIC_TEST

Blood,urine and imaging biomarkers for early diagnosis and prediction of prognosis.

Diabetes Group

Biomarkers

Intervention Type DIAGNOSTIC_TEST

Blood,urine and imaging biomarkers for early diagnosis and prediction of prognosis.

Hyperuricemia

Biomarkers

Intervention Type DIAGNOSTIC_TEST

Blood,urine and imaging biomarkers for early diagnosis and prediction of prognosis.

Obesity

Biomarkers

Intervention Type DIAGNOSTIC_TEST

Blood,urine and imaging biomarkers for early diagnosis and prediction of prognosis.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biomarkers

Blood,urine and imaging biomarkers for early diagnosis and prediction of prognosis.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The diagnosis of metabolic diseases were confirmed;
* Be able to understand the process of the research;
* Volunteer for participation and be able to sign the informed consent.

Exclusion Criteria

* Age \<18 yrs or \>80yrs;
* Patients with primary and secondary glomerular diseases
* Patients with other comorbidities that could affect the volume or the components of the kidney, such as renal cysts, polycystic kidney disease, medullary sponge kidney, hydronephrosis, renal artery stenosis, renal vein thrombosis and/or renal tumors;
* Contraindications for MRI examination;
* Pregnant or lactation patients;
* Patients with unstable vital signs, failure of other organs or dysphoria.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Peking Union Medical College Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Limeng Chen

director of the department of nephrology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Limeng Chen

Role: PRINCIPAL_INVESTIGATOR

Peking Union Medical College Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yan Liu

Role: CONTACT

+86-15811568692

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Yan Liu

Role: primary

+86-15811568692

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

JS-2136

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.